AKT1 and breast neoplasm: In certain cases, targeting direct activators such as TBL2 and PRMT5 has been explored as a potential therapeutic strategy for breast tumors (Lu et al., 2024), or even the complete inhibition of EGFR/PI3K/AKT and mTOR mediated pathways using natural compounds (Ganesan et al., 2024).